Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation

Journal of Clinical Gastroenterology

Volumn 46, Issue 8, 2012, Pages 700-708

  Gordon, Fredric D ^a   Kwo, Paul ^b   Ghalib, Reem ^c   Crippin, Jeffrey ^d   Vargas, Hugo E ^e   Brown, Kimberly A ^f   Schiano, Thomas ^g   Chaudhri, Eirum ^h   Pedicone, Lisa D ^h   Brown Jr , Robert S ⁱ  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Texas Digestive Disease Consultants   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g MOUNT SINAI MEDICAL CENTER   (United States)

^h College of Physicians and Surgeons ^*  (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

anemia; genotype; hepatitis; multicenter; peginterferon; predictor; prospective; ribavirin; transplant

Indexed keywords

CYCLOSPORIN; ERYTHROPOIETIN; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ANTIVIRAL THERAPY; APPETITE; ARTICLE; CELLULITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTION; COLITIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EARLY VIROLOGIC RESPONSE; FATIGUE; FEMALE; FEVER; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INSOMNIA; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RAPID VIROLOGIC RESPONSE; RECURRENT INFECTION; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865470113     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825833be     Document Type: Article

References (114)

1. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686.
2. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815-820.
3. Ballardini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl. 2002;8:10-20.
4. Guerrero RB, Batts KP, Burgart LJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: A molecular and histologic study. Mod Pathol. 2000;13:229-237.
5. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14-S18.
6. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl. 2006;12:1805-1812.
7. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007;13:1100-1108.
8. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology. 2007;132:1746-1756.
9. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (a-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005;43:53-59.
10. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon a2b and ribavirin: An open-label series. Transplantation. 2004;77: 190-194.
11. Ross AS, Bhan AK, Pascual M, et al. Pegylated interferon a-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant. 2004;18:166-173.
12. Mukherjee S, Lyden E. Impact of pegylated interferon a-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: An open-label series. Liver Int. 2006;26:529-535.
13. Bizollon T, Pradat P, Mabrut J-Y, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant. 2007;7:448-453.
14. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation. 2004;78:1303-1307.
15. Rahim N, Prosser C, Bowlus C, et al. Increasing adherence to therapy for recurrent hepatitis C after liver transplantation by starting at lower drug doses and adding growth factors. Pract Gastroenterol. 2007;31:24-33.
16. Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008;14: 53-58.
17. Samuel D, Bizollon T, Feray C, et al. Interferon-a 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology. 2003; 124:642-650.
18. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274-287.
19. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118-124.
20. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 2004;10:850-858.
21. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology. 2005;41:289-298.
22. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255-262.
23. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766-1777.
24. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant. 2006;6:2348-2355.
25. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006;12:1067-1076.
26. Goto K, Watashi K, Murata T, et al. Evaluation of the antihepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun. 2006;343:879-884.
27. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12:51-57.
28. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: Predictors of response and long-term outcome. Transplantation. 2009;88: 1214-1221.
29. Firpi RJ, Soldevila-Pico C, Morelli GG, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: A randomized pilot study. Dig Dis Sci. 2010;55:196-203.
30. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98:2491-2499.
31. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-1311.
32. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology. 2011;54:3-5. 637-648
33. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (GLOBOCAN web site). Lyon, France International Agency for Research on Cancer; 2010. Available at: http:// globocan.iarc.fr. Accessed September 22, 2011.
34. Shah MA, Kelsen DP. Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437-447.
35. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: Eighteen-year experience at a single institution. J Gastrointest Surg. 2010;9:718-725.
36. Howlander N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2008 (SEER web site). November 2010. Available at: http://seer.cancer.gov/ csr/1975-2008. Accessed September 22, 2011.
37. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J ClinOncol. 2006;24:2137-2150.
38. Ahn HS, Lee HJ, Hahn S, et al. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116: 5592-5598.
39. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419-424.
40. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
41. Shimoyama S, Itouji T, Enomoto H, et al. Our experiences of best supportive care for gastric cancer patients (in Japanese with English abstract). Gan To Kagaku Ryoho. 2010;37: 259-262.
42. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011;12:96-106.
43. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12:204-213.
44. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
45. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008;9:215-221.
46. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
47. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673.
48. Okines AF, Norman AR,McCloud P, et al.Meta-analysis of the REAL-2 and ML17032 trials: Evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-1534.
49. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
50. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
51. Schluter B, Gerhards R, Strumberg D, et al. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136:1389-1400.
52. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
53. Beltran GB, Yabar BA. HER2 expression in gastric cancer in Peru (in Spanish with English abstract). Rev Gastroenterol Peru. 2010;30:324-327.
54. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797-805.
55. Im SA, Kim JW, Kim JS, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol. 2011;20:94-100.
56. Tanner M, Hollme'n M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-278.
57. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53-59.
58. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
59. Maresch J, Schoppmann SF, Thallinger CM, et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol. 2011. [Epub ahead of print].
60. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
61. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
62. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
63. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium, 2009; San Antonio, TX, abstract 62.
64. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
65. Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist. 2011;16:800-810.
66. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27:5838-5847.
67. Corte's-Funes H, Rivera F, Alé s I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol. 2007;18S. Abstract 4613.
68. Nicholas G, Cripps C, Au H-J, et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2. European Society for Medical Oncology Meeting, 2006; Istanbul, Turkey, abstract 1105P.
69. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
70. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. ASCO Gastrointestinal Cancers Symposium, 2010; Orlando, FL, abstract 7.
71. Kang Y-K, Shen L, Lichinitser M, et al. Self-rated pain assessment by patients with HER2-positive advanced gastric/ GEJ cancer treated with 5-FU/capecitabine and cisplatin with or without trastuzumab: Exploratory QOL analysis from the Phase III ToGA study. Gastroenterology. 2011;140:S-204.
72. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
73. Ohtsu A, Wang L, Lim HY, et al. Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastro-oesophageal junction cancer. WCGC 2010; Barcelona, Spain, poster O-0011.
74. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-lifeoriented endpoint for comparing therapies. Biometrics. 1989; 45:781-795.
75. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
76. Chung HC, Bang Y-J, Van Cutsem E, et al. (Q)-TWIST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/ FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. J Clin Oncol. 2010;28. Abstract 4048.
77. Powell WC, Zielinski D, Ranger-Moore J, et al. Determining the HER2 status in gastric cancer: A method comparison study of two patient cohorts. ASCO Gastrointestinal Cancers Symposium, 2010; Orlando, FL, abstract 17.
78. Herceptin summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/ human/000278/WC500074922. pdf. Accessed September 22, 2011.
79. NCCN clinical practice guidelines in oncology (NCCN guidelinest). Gastric Cancer. Version 2.2011. http://www.nccn.org/ professionals/physician-gls/pdf/ gastric.pdf. Accessed September 22, 2011.
80. Herceptin prescribing information. Available at: http:// www.accessdata.fda.gov/drugsatfda-docs/label/2010/103792s5 256lbl.pdf. Accessed September 26, 2011.
81. A study of capecitabine (Xeloda) in combination with trastuzumab (Herceptin) and oxaliplatine in patients with resectable gastric cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01130337. Accessed September 27, 2011.
82. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011;22:2610-2615.
83. Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31:2332-2348.
84. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744-4749.
85. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100:1092-1103.
86. Lin NU, Carey LA, Younger J, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
87. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
88. Amir E, Ocana A, Seruga B, et al. Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev. 2010;36: 410-415.
89. Yip AY, Tse LA, Ong EY, et al. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: A systematic review. Anticancer Drugs. 2010;21:487-493.
90. LOGiC - lapatinib optimization study in ErbB2 (HER2) positive gastric cancer: A phase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib. Available at: http://clinicaltrials.gov/ct2/show/NCT00680901. Accessed September 22, 2011.
91. Hecht J, Bang Y-J, Sobrero A, et al. A phase III study of CapeOx +/lapatinib in HER2 positive locally advanced/ metastatic upper gastrointestinal adenocarcinoma: interim safety results. European Society for Medical Oncology Meeting 2009; Berlin, Germany, poster 6.584.
92. Lapatinib in combination with weekly paclitaxel in patients with ErbB2 amplified advanced gastric cancer. Available at: http://clinicaltrials.gov/ct2/ show/NCT00486954. Accessed September 22, 2011.
93. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol. 2010;28. Abstract 4057.
94. Hughes JB, Berger C, Rodland MS, et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther. 2009;8:1885-1892.
95. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138-1144.
96. A Study of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT01461057. Accessed February 23, 2012.
97. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res. 2008;68:9280-9290.
98. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (TDM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2010;128:347-356.
99. Hurvitz S, Dirix L, Kocsis J, et al. Trastuzumab emtansine (TDM1) versus trastuzumab plus docetaxel (H+T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). European Society for Medical Oncology Meeting, 2010; Milan, Italy, abstract 5001.
100. Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2- positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study. European Society for Medical Oncology Meeting, 2010; Milan, Italy, abstract LBA3.
101. Chugai (press release). Anti-cancer agent, Herceptins obtained approval for additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection. Available at: http://www.chugai- pharm.co. jp/hc/ss/english/news/detail/20110310150000.html. Accessed September 22, 2011.
102. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402.
103. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852-1857.
104. Sergina NV, Rausch M, Wang D, et al. Escape from HERfamily tyrosine kinase inhibitor therapy by the kinaseinactive HER3. Nature. 2007;445:437-441.
105. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127.
106. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-1624.
107. Zabrecky JR, Lam T, McKenzie SJ, et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem. 1991;266: 1716-1720.
108. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptinresistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65:473-482.
109. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99:783-791.
110. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol. 2008;26: 1789-1796.
111. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
112. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium, 2010; San Antonio, TX, abstract S3-3.
113. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). San Antonio Breast Cancer Symposium, 2010; San Antonio, TX, abstract S3-2.
114. Bang Y, Kim YW, Yang H, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. J Clin Oncol. 2011;29. abstract LBA4002.